Bracco Diagnostics, Inc.
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Employees
- -
- Market Cap
- -
Clinical Trials
51
Trial Phases
6 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (39 trials with phase data)• Click on a phase to view related trials
Lumason® Infusion vs. Bolus Administrations
- Conditions
- Heart Diseases
- Interventions
- Drug: Sulfur Hexafluoride Lipid Type A Microspheres 25 MG Injection Powder for Suspension [LUMASON]
- First Posted Date
- 2024-05-06
- Last Posted Date
- 2024-05-06
- Lead Sponsor
- Bracco Diagnostics, Inc
- Target Recruit Count
- 106
- Registration Number
- NCT06400004
- Locations
- 🇺🇸
Piedmont Heart Institute, Atlanta, Georgia, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Oregon Health and Sciences University, Portland, Oregon, United States
Study With Oral Isovue in Abdominopelvic CT
- Conditions
- Patients Requiring Abdominopelvic CT With Oral Administration of Contrast
- First Posted Date
- 2020-07-01
- Last Posted Date
- 2023-02-08
- Lead Sponsor
- Bracco Diagnostics, Inc
- Target Recruit Count
- 218
- Registration Number
- NCT04453059
- Locations
- 🇺🇸
Akron Children's Hospital, Akron, Ohio, United States
Optimal Timing of BR55 CEUS of the Ovaries
- First Posted Date
- 2020-01-30
- Last Posted Date
- 2024-08-23
- Lead Sponsor
- Bracco Diagnostics, Inc
- Target Recruit Count
- 3
- Registration Number
- NCT04248153
- Locations
- 🇺🇸
Stanford University Medical Center, Palo Alto, California, United States
Thyroid Function of Pediatric Subjects Following Isovue® Administration
- First Posted Date
- 2018-12-19
- Last Posted Date
- 2025-07-30
- Lead Sponsor
- Bracco Diagnostics, Inc
- Target Recruit Count
- 17
- Registration Number
- NCT03779906
- Locations
- 🇺🇸
Phoenix Children's Hospital, Phoenix, Arizona, United States
🇺🇸Children's Hospital Medical Center of Akron, Akron, Ohio, United States
🇺🇸Medical University of South Carolina (MUSC), Charleston, South Carolina, United States
Evaluation of Safety and Efficacy of ProHance in Pediatric Patients <2yrs
- Conditions
- Central Nervous System DiseasesCentral Nervous System Neoplasms
- First Posted Date
- 2018-11-21
- Last Posted Date
- 2020-01-23
- Lead Sponsor
- Bracco Diagnostics, Inc
- Target Recruit Count
- 125
- Registration Number
- NCT03750188
- Locations
- 🇺🇸
Medical University of South Carolina, Charleston, South Carolina, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 10
- Next